Supernus Pharmaceuticals (NASDAQ:SUPN) Upgraded at StockNews.com
StockNews.com upgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN – Free Report) from a buy rating to a strong-buy rating in a research note published on Friday. Separately, Cantor Fitzgerald reiterated a “neutral” rating and set a $36.00 price objective on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 26th. Get Our Latest Stock […]
StockNews.com upgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN – Free Report) from a buy rating to a strong-buy rating in a research note published on Friday. Separately, Cantor Fitzgerald reiterated a “neutral” rating and set a $36.00 price objective on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 26th. Get Our Latest Stock […]
